June 29, 2018 08:17 AM EDT

How does the first half of 2018 measure up against the last 7 years for biotech IPOs?

John Carroll

Editor & Founder

For some added perspective on the second-quarter spike in biotech IPOs, we’re offering you Renaissance Capital’s updated snapshot on the last 7 years. Remember …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How does the first half of 2018 measure up against the last 7 years for biotech IPOs?

John Carroll

Editor & Founder

Sign up to read this article for free.

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals

How does the first half of 2018 mea­sure up against the last 7 years for biotech IPOs?

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Biose­cure com­pro­mise could add ex­ec­u­tive re­view process for named com­pa­nies, sources say

Af­ter Unit­ed­Health­care CEO killing, health­care in­dus­try faces a new se­cu­ri­ty re­al­i­ty

Eli­av Barr de­fends Mer­ck­'s LaNo­va deal, but cau­tions VEGF bis­pecifics have yet to de­liv­er ma­ture da­ta

Lil­ly con­tin­ues to ex­pand its em­pire of GLP-1 fac­to­ries with new $3B build­out

GSK's third new pact of the week fo­cus­es on Alzheimer's with start­up Mu­na Ther­a­peu­tics

FDA spells out new ex­pe­dit­ed with­draw­al pro­ce­dures for ac­cel­er­at­ed ap­provals

How does the first half of 2018 measure up against the last 7 years for biotech IPOs?

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals